V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220021985 | 220005332 | 1.7 | 65.4 | Curative (C) | 2013-10-27 | 2014-01-06 | AML17 TRIAL | Y | N | 220020646 | AML17 TRIAL |
| 220021986 | 220005340 | 1.77 | 77.1 | Adjuvant (A) | 2014-03-08 | 2014-08-08 | AML17 TRIAL | 02 | N | 220020654 | AML17 TRIAL |
| 220021987 | 220005353 | 1.67 | 103 | Curative (C) | 2019-09-20 | 2019-09-24 | FLAG + Idarubicin | 02 | N | 220020673 | FLAG + IDARUBICIN |
| 220021988 | 220005360 | 1.98 | 66.6 | Curative (C) | 2015-07-21 | 2015-10-02 | AML17 TRIAL | Y | N | 220020676 | AML17 TRIAL |
| 220021989 | 220005390 | 1.53 | 109.9 | Adjuvant (A) | 2016-08-22 | 2017-09-26 | FLAG + Idarubicin | 01 | N | 220020746 | FLAG + IDARUBICIN |
| 220021991 | 220020683 | 1.85 | 67.5 | Palliative (P) | 2019-05-12 | 2019-08-14 | Trial Unspecified | Y | null | 220021137 | TRIAL |
| 220021992 | 220012909 | 1.85 | 77 | Curative (C) | 2019-01-08 | 2019-01-19 | Trial Unspecified | N | N | 220021161 | TRIAL |
| 220021993 | 220005534 | 1.54 | 84.7 | Curative (C) | 2014-09-02 | 2014-09-02 | Trial Unspecified | Y | N | 220021175 | TRIAL |
| 220021994 | 220005556 | 1.65 | 0 | Curative (C) | 1536-03-08 | 1536-03-08 | Trial Unspecified | Y | N | 220021255 | TRIAL |
| 220021995 | 220017130 | 1.68 | 109.6 | Curative (C) | 2018-08-30 | 2018-10-19 | AML 19 TRIAL | Y | N | 220021572 | AML19 TRIAL |
| 220021997 | 220005718 | 1.62 | 84.6 | Disease modification (D) | 2017-06-11 | 2017-11-16 | AML 19 TRIAL | 01 | N | 220021690 | AML19 TRIAL |
| 220021998 | 220005723 | 1.58 | 64.4 | null | 2018-12-14 | 2018-12-17 | AML 19 TRIAL | Y | null | 220021720 | AML19 TRIAL |
| 220021999 | 220005726 | 1.7 | 83.6 | Curative (C) | 2018-10-12 | 2019-01-12 | AML 19 TRIAL | Y | N | 220021721 | AML19 TRIAL |
| 220022000 | 220005761 | 1.78 | 54 | Not known (9) | 2017-07-21 | 2017-09-27 | Trial Unspecified | 01 | N | 220021789 | TRIAL |
| 220022002 | 220005809 | 1.61 | 84.7 | Curative (C) | 2019-10-10 | 2019-10-14 | Trial Unspecified | N | N | 220021942 | TRIAL |
| 220022003 | 220005821 | 1.83 | 90.4 | Curative (C) | 2014-05-11 | 2014-05-20 | Trial Unspecified | Y | N | 220021958 | TRIAL |
| 220022004 | 220013080 | 0 | 70.8 | Disease modification (D) | 2013-10-06 | 2014-05-29 | Hydroxycarbamide | 02 | N | 220021966 | HYDROXYCARBAMIDE |
| 220022005 | 220005879 | 1.48 | null | Palliative (P) | 2014-01-30 | 2014-02-06 | Cytarabine Low Dose | N | N | 220022138 | CYTARABINE |
| 220022006 | 220005887 | null | 87.1 | Disease modification (D) | 2014-06-26 | 2014-09-18 | Hydroxycarbamide | null | N | 220022174 | HYDROXYCARBAMIDE |
| 220022007 | 220005902 | 1.83 | 65.3 | Palliative (P) | 2014-10-22 | 2014-10-22 | Hydroxycarbamide | N | N | 220022212 | HYDROXYCARBAMIDE |
| 220022008 | 220017210 | null | 82.6 | Palliative (P) | 2016-01-24 | 2016-06-06 | Hydroxycarbamide | 02 | N | 220022379 | HYDROXYCARBAMIDE |
| 220022009 | 220005970 | null | 58.3 | Palliative (P) | 2019-07-18 | 2019-07-18 | Hydroxycarbamide | 02 | null | 220022475 | HYDROXYCARBAMIDE |
| 220022010 | 220005975 | null | 77.9 | Curative (C) | 2018-04-11 | 2018-04-14 | Hydroxycarbamide | N | null | 220022478 | HYDROXYCARBAMIDE |
| 220022011 | 220017229 | 1.75 | null | Palliative (P) | null | 2014-09-12 | Hydroxycarbamide | Y | N | 220022679 | HYDROXYCARBAMIDE |
| 220022012 | 220006026 | 1.66 | 68 | Curative (C) | 2014-09-25 | 2014-09-25 | Cytarabine low (10to20mg/m2) IV/SC | 2 | N | 220022722 | CYTARABINE |
| 220022013 | 220006047 | 1.74 | 92.9 | null | 2014-03-18 | 2014-04-27 | CYTARABINE | N | N | 220022807 | CYTARABINE |
| 220022014 | 220006063 | null | 43 | Disease modification (D) | 2019-04-03 | 2019-04-07 | AML Interim Guidelines FLA -Ida | N | N | 220022911 | NOT MATCHED |
| 220022015 | 220006071 | 1.71 | 54 | Curative (C) | 2015-07-08 | 2015-10-07 | AML Interim Guidelines FLA -Ida | N | N | 220022988 | NOT MATCHED |
| 220022017 | 220006091 | 1.63 | 30.4 | Disease modification (D) | null | 2014-12-16 | AML MyeChild 01 FLA | null | null | 220023007 | NOT MATCHED |
| 220022018 | 220006101 | null | 52 | Curative (C) | 2018-08-07 | 2018-08-08 | AML Relapsed FLA - DaunoXome | null | null | 220023070 | NOT MATCHED |
| 220022019 | 220006160 | 0 | 81.6 | Disease modification (D) | 2014-03-13 | 2014-03-15 | Cytarabine Low Dose | N | N | 220023340 | CYTARABINE |
| 220022020 | 220006164 | 1.76 | 65.4 | Palliative (P) | 2018-10-29 | 2018-11-01 | null | N | N | 220023346 | NOT MATCHED |
| 220022021 | 220006182 | 1.62 | 64.4 | Disease modification (D) | 2018-05-21 | 2018-05-22 | Hydroxycarbamide | 02 | N | 220023471 | HYDROXYCARBAMIDE |
| 220022022 | 220006184 | null | 70 | Curative (C) | 2016-11-18 | 2017-01-20 | Cytarabine Low Dose | N | null | 220023478 | CYTARABINE |
| 220022023 | 220006190 | null | 88.3 | Curative (C) | null | 2019-03-14 | Cytarabine Low Dose | N | null | 220023489 | CYTARABINE |
| 220022024 | 220006231 | 1.8 | 71.8 | Palliative (P) | 2014-01-16 | 2014-07-03 | Cytarabine + Etoposide + Tretinoin | 02 | N | 220023646 | NOT MATCHED |
| 220022025 | 220006250 | 1.74 | 18 | Curative (C) | 2018-11-06 | 2019-03-14 | APML SR Ind ATO + ATRA | Y | N | 220023701 | NOT MATCHED |
| 220022026 | 220006258 | null | null | null | 2016-09-16 | 2017-09-14 | Hydroxycarbamide | Y | N | 220023737 | HYDROXYCARBAMIDE |
| 220022027 | 220013372 | 1.78 | null | Palliative (P) | 2018-11-10 | 2018-11-10 | Hydroxycarbamide | null | null | 220023759 | HYDROXYCARBAMIDE |
| 220022028 | 220013379 | -1 | 69 | Curative (C) | null | 2013-10-27 | AML MyeChild 01 A Mitozantrone/Cytarabine | N | N | 220023793 | NOT MATCHED |
| 220022029 | 220006278 | 1.74 | 64.6 | Disease modification (D) | 2015-09-11 | 2015-09-11 | Hydroxycarbamide | null | null | 220023811 | HYDROXYCARBAMIDE |
| 220022030 | 220013388 | 1.08 | 78 | Curative (C) | 2017-07-20 | 2018-03-15 | CYTARABINE | 2 | N | 220023821 | CYTARABINE |
| 220022031 | 220006297 | null | null | Disease modification (D) | null | 2019-05-20 | AML MyeChild 01 FLA | 02 | N | 220023866 | NOT MATCHED |
| 220022032 | 220006341 | null | 99 | Curative (C) | 2017-07-26 | 2017-08-10 | null | null | null | 220024098 | NOT MATCHED |
| 220022033 | 220006399 | null | null | Disease modification (D) | 2016-07-23 | 2016-07-23 | Rituximab | N | N | 220024326 | RITUXIMAB |
| 220022034 | 220006409 | 0 | 65.2 | Curative (C) | 2015-11-23 | 2015-11-23 | Alemtuz+Fludara+Melphalan RIC MUD | null | null | 220024353 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022035 | 220006456 | null | 78 | Disease modification (D) | 2018-09-30 | 2018-10-03 | AML 18 Pilot Trial | N | N | 220024528 | PILOT TRIAL |
| 220022036 | 220022253 | null | 63.5 | Curative (C) | 2019-04-05 | 2019-07-16 | AML18 PILOT TRIAL | N | N | 220024708 | PILOT TRIAL |
| 220022037 | 220021452 | 0 | 127.3 | Curative (C) | 2015-01-29 | 2015-01-29 | Rituximab | 2 | N | 220024810 | RITUXIMAB |
| 220022038 | 220022340 | 1.78 | 101.5 | Curative (C) | 2016-03-29 | 2016-03-29 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 2 | N | 220024847 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |